|1.||Rogowski, Roberta: 7 articles (02/2012 - 11/2007)|
|2.||Roth, Thomas: 6 articles (02/2012 - 11/2007)|
|3.||Lankford, Alan: 5 articles (02/2012 - 11/2007)|
|4.||Ludington, Elizabeth: 5 articles (02/2012 - 10/2010)|
|5.||Jochelson, Philip: 4 articles (10/2011 - 10/2010)|
|6.||Oien, Hal: 4 articles (03/2008 - 01/2003)|
|7.||Epstein, Joel B: 4 articles (03/2008 - 01/2003)|
|8.||Truelove, Edmond L: 4 articles (03/2008 - 01/2003)|
|9.||Przewlocka, B: 3 articles (05/2015 - 10/2005)|
|10.||Mika, Joanna: 3 articles (02/2015 - 01/2013)|
|1.||Sleep Initiation and Maintenance Disorders (Insomnia)
01/01/2012 - "Low-dose doxepin may have a unique role in the treatment of insomnia in elderly patients given its tolerability, documented efficacy, and lack of important adverse effects."
08/01/2010 - "Oral, low-dose doxepin 6 mg was also significantly more effective than placebo in a large, well designed trial modelling transient insomnia in healthy adults, according to polysomnographic recordings (e.g. "
08/01/2010 - "In three large, well designed, phase III trials in adult or elderly patients with chronic primary insomnia, oral, low-dose doxepin 3 or 6 mg once daily improved wake time after sleep onset, total sleep time and sleep efficiency to a significantly greater extent than placebo. "
10/01/2008 - "In this 2-night study of elderly adults with primary insomnia, doxepin doses of 1 mg, 3 mg, and 6 mg were well tolerated and produced significant improvement in objective and subjective sleep maintenance and duration endpoints that persisted into the final hour of the night. "
07/01/2013 - "Compared to placebo, doxepin improved the Insomnia Severity Index (-9 ± 5.4 vs. -2 ± 3.9, p = 0.03), the SCOPA-night score (-5.2 ± 1.5 vs. -2.3 ± 2.8, p = 0.049), the Pittsburgh Sleep Quality Index-sleep disturbances subscale (-0.5 ± 0.5 vs 0.2 ± 0.4, p = 0.02), and both patient and examiner-rated clinical global impression of change (1.7 ± 0.8 vs. 0.5 ± 0.8, p = 0.03 and 1.4 ± 0.5 vs. 0.3 ± 0.5, p = 0.003). "
12/01/1995 - "Twenty-four hours after initiation of treatment, and continuing throughout the remainder of the study, patients treated with doxepin cream experienced significantly greater pruritus relief than did vehicle-treated patients as determined by all efficacy parameters (P < .002). "
10/01/1994 - "Pruritus severity scores demonstrated significantly greater improvement with topical doxepin at each study visit (p < 0.01). "
08/01/1999 - "Pruritus relief and lessening of pruritus severity were significantly greater with doxepin/TAC than doxepin alone. "
10/01/1994 - "At each of three visits, the physician's global evaluation for relief of pruritus also showed significant improvement in the doxepin treatment group (p < 0.01). "
08/01/1999 - "Topically applied doxepin is safe and effective therapy for pruritus."
08/01/1982 - "The efficacy of doxepin compared with that of placebo was thus documented in several depressive and pain parameters, indicating that doxepin is a valuable treatment for patients with chronic pain and depression."
01/01/2003 - "The purpose of this study was to assess the anesthetic effect of doxepin oral rinse in normal subjects to identify the duration of effect and to contrast the anesthetic effect with reported pain relief in patients with oral mucosal lesions. "
12/01/2001 - "The results of this single dose trial suggest that topical doxepin rinse has significant ability to provide clinically significant pain relief in patients with mucosal damage with an extended duration of effect."
03/01/1984 - "Doxepin's effects on chronic pain and depression: a controlled study."
01/01/2015 - "In this sense, we have developed new doxepin mucoadhesive films able of reducing pain and increasing the effectiveness of treatment. "
|4.||Neuralgia (Stump Neuralgia)
05/21/2015 - "The aims of this paper were to test the effects of two classic TCAs, doxepin and amitriptyline, in naïve animals and in a model of neuropathic pain and to determine the role of cytokine activation in the effects of these drugs. "
05/21/2015 - "Effects of chronic doxepin and amitriptyline administration in naïve mice and in neuropathic pain mice model."
06/01/2000 - "Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study."
06/18/2008 - "Application of lidocain 5%, capsaicin 0.025-0.075% and doxepin 3.3% is effective, although moderately in peripheric neuropathic pain with allodynia and should be considered as a therapeutic option. "
12/01/2009 - "Efficacy of tramadol in combination with doxepin or venlafaxine in inhibition of nociceptive process in the rat model of neuropathic pain: an isobolographic analysis."
|5.||Atopic Dermatitis (Atopic Eczema)
02/01/1999 - "The addition of topical doxepin to corticosteroid therapy: an improved treatment regimen for atopic dermatitis."
08/01/1999 - "Twenty-four subjects with atopic dermatitis received either doxepin or doxepin/TAC cream 4 times daily for 7 days in a randomized, double-blind, controlled trial. "
08/01/1999 - "Pharmacokinetics of doxepin in subjects with pruritic atopic dermatitis."
10/01/1994 - "Topical doxepin is effective in reducing pruritus in patients with atopic dermatitis. "
10/01/1994 - "The current study was undertaken to compare the efficacy and safety of topical 5% doxepin cream in relieving pruritus associated with atopic dermatitis. "
|3.||Tricyclic Antidepressive Agents (Tricyclic Antidepressants)
|6.||Antidepressive Agents (Antidepressants)
|7.||Mustard Gas (Sulfur Mustard)
|9.||Histamine Antagonists (Antihistamines)
|5.||Deep Brain Stimulation